CA19-9 as a therapeutic target in pancreatitis

descriptionPublicationkeyboard_double_arrow_right Article , Other literature type 01 Dec 2019Publisher:AME Publishing CompanyJournal:Annals of Translational Medicine, volume 7, pages S318-S318 (issn: 2305-5839, eissn: 2305-5847,

Copyright policy )

Authors: Shingo, Kato; Kazufumi, Honda;

doi: 10.21037/atm.2019.09.161

pmid: 32016036

pmc: PMC6976502

CA19-9 as a therapeutic target in pancreatitis

- Summary
- Metrics

Abstract

The glycan carbohydrate antigen 19-9 (CA19-9) is one of the most important and widely used biomarkers for pancreatic cancer. In 1979, Koprowski et al. first described CA 19-9 as a tumor antigen recognized by the monoclonal antibody NS19-9 (1).

Related Organizations

Yokohama City University
Japan

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	3
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average